Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 9;36(1):98–108. doi: 10.1080/14756366.2020.1843452

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — In vitro anticancer activity of dual MAP4K5 and TAOK1 inhibitors. (A) The proliferation effect was determined by SRB assay. Colorectal (HT-29 and HCT116) and lung (H1299) cancer cell lines were treated with the indicated compounds at 10 μM for 48 h (left figure). The cell survival was assessed by MTT assay. Three cancer cell lines were treated with the indicated compounds at 30 μM for 72 h (right figure). HT-29, HCT116 and H1299 cancer cell lines were incubated with different concentrations of compound 1 for (B) 48 h to assess anti-proliferative activity and for (C) 72 h to evaluate anti-survival activity. The results are based on at least three independent experiments.